Data_Sheet_1_Genetically predicted serum metabolites mediate the association between inflammatory proteins and polycystic ovary syndrome: a Mendelian randomization study.CSV by Ming-Jie Jia (18267391)

“…</p>Results<p>The IVW method revealed that the inflammatory proteins IFN-γ (p-value = 0.037, OR = 1.396, 95% CI = 1.020–1.910) and CCL7 (p-value = 0.033, OR = 1.294, 95% CI = 1.021–1.641) were associated with an increased risk of PCOS, while IL-6 (p-value = 0.015, OR = 0.678, 95% CI = 0.495–0.929) and MMP-10 (p-value = 0.025, OR = 0.753, 95% CI = 0.587–0.967) were associated with a decreased risk. No significant evidence suggested an effect of genetically predicted PCOS on inflammatory proteins. …”

Data_Sheet_2_Genetically predicted serum metabolites mediate the association between inflammatory proteins and polycystic ovary syndrome: a Mendelian randomization study.CSV by Ming-Jie Jia (18267391)

“…</p>Results<p>The IVW method revealed that the inflammatory proteins IFN-γ (p-value = 0.037, OR = 1.396, 95% CI = 1.020–1.910) and CCL7 (p-value = 0.033, OR = 1.294, 95% CI = 1.021–1.641) were associated with an increased risk of PCOS, while IL-6 (p-value = 0.015, OR = 0.678, 95% CI = 0.495–0.929) and MMP-10 (p-value = 0.025, OR = 0.753, 95% CI = 0.587–0.967) were associated with a decreased risk. No significant evidence suggested an effect of genetically predicted PCOS on inflammatory proteins. …”

Table 1_Elucidating the causal relationship between 486 genetically predicted blood metabolites and the risk of gastric cancer: a comprehensive Mendelian randomization analysis.xls... by Lei Qian (292302)

“…</p>Results<p>The MVMR analysis revealed a significant association between genetically predicted elevated levels of tryptophan (odds ratio [OR] = 0.523, 95% confidence interval [CI] = 0.313–0.872, p = 0.013), nonadecanoate (19:0) (odds ratio [OR] = 0.460, 95% confidence interval [CI] = 0.225–0.943, p = 0.034), and erythritol (odds ratio [OR] = 0.672, 95% confidence interval [CI] = 0.468–0.930, p = 0.016) with a decreased risk of gastric cancer. …”

Tobacco and alcohol use are the risk factors responsible for the greatest burden of head and neck cancers: a study from the Global Burden of Disease Study 2019 by Yue Yuan (113839)

“…Interestingly, the ASIRs for laryngeal cancer showed a decreasing trend over the studied time frame from 1990 to 2019. …”

Data Sheet 1_Reduction of orexin-expressing neurons and a unique sleep phenotype in the Tg-SwDI mouse model of Alzheimer’s disease.pdf by Yan Wu (70890)

“…<p>Sleep disturbances are common in Alzheimer’s disease (AD) and AD-related dementia (ADRD). We performed a sleep study on Tg-SwDI mice, a cerebral amyloid angiopathy (CAA) model, and age-matched wild-type (WT) control mice. …”

Supplementary file 1_Dietary composition and fasting regimens differentially impact the gut microbiome and short-chain fatty acid profile in a Pakistani cohort.docx by Farzana Gul (7119200)

“…Purpose<p>Fasting is known to have beneficial effects on human physiology and health due to changes in gut microbiota and its associated metabolites. We investigated the effects of intermittent and Ramadan fasting on the gut microbial composition, diversity, and short-chain fatty acid (SCFA) profile in a Pakistani population.…”

Data Sheet 2_Dietary composition and fasting regimens differentially impact the gut microbiome and short-chain fatty acid profile in a Pakistani cohort.xlsx by Farzana Gul (7119200)

“…Purpose<p>Fasting is known to have beneficial effects on human physiology and health due to changes in gut microbiota and its associated metabolites. We investigated the effects of intermittent and Ramadan fasting on the gut microbial composition, diversity, and short-chain fatty acid (SCFA) profile in a Pakistani population.…”

Data Sheet 1_Dietary composition and fasting regimens differentially impact the gut microbiome and short-chain fatty acid profile in a Pakistani cohort.csv by Farzana Gul (7119200)

“…Purpose<p>Fasting is known to have beneficial effects on human physiology and health due to changes in gut microbiota and its associated metabolites. We investigated the effects of intermittent and Ramadan fasting on the gut microbial composition, diversity, and short-chain fatty acid (SCFA) profile in a Pakistani population.…”

Table 1_Inflammatory markers CRP and WBC as predictors of liver function impairment in multiple injury trauma patients: a repeated measures analysis.docx by Gang Wang (36685)

“…Aims<p>To investigate the relationship between liver function indices (AST, ALT, GGT) and inflammatory markers (CRP, white blood cell count) in multiple injury patients at different time points post-trauma.</p>Methods<p>We retrospectively analyzed 114 patients with multiple injuries admitted to a tertiary trauma center in Zhejiang Province (January 2023–December 2024). …”

Image 1_Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.tiff by José De Jesus Bravo-Silva (21898316)

“…Melatonin, a hormone with antioxidant and immunomodulatory properties, has previously been shown to inhibit Japanese encephalitis virus (JEV) replication through RhoA pathway modulation.…”

Image 3_Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.tiff by José De Jesus Bravo-Silva (21898316)

“…Melatonin, a hormone with antioxidant and immunomodulatory properties, has previously been shown to inhibit Japanese encephalitis virus (JEV) replication through RhoA pathway modulation.…”

Image 2_Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.tiff by José De Jesus Bravo-Silva (21898316)

“…Melatonin, a hormone with antioxidant and immunomodulatory properties, has previously been shown to inhibit Japanese encephalitis virus (JEV) replication through RhoA pathway modulation.…”

Data Sheet 1_Case Report: Metabolic alterations and cholesterol esterification in a low-grade diffuse astrocytoma patient who progressed to glioblastoma at recurrence.docx by Omkar B. Ijare (22274167)

“…Particularly, IDH wildtype (IDHwt) diffuse astrocytomas harboring TERT promoter (TERTp) mutations, classified as molecular GBM under the 2021 WHO classification, may exhibit distinct metabolic and epigenetic features compared to histological WHO Grade 4 GBMs. Here, we conducted a detailed metabolomic comparison of tumor specimens from a patient initially diagnosed with WHO Grade 2 IDHwt diffuse astrocytoma carrying TERTp mutation, who subsequently progressed to a histologically confirmed WHO Grade 4 GBM upon recurrence.…”

Data Sheet 1_CARTOON-based educational intervention for children to foster hygiene knowledge and emotional resilience in preschool children: a randomized controlled trial.pdf by Philipp Steinbauer (10792029)

“…While children's physical health may not be severely affected, their psychological well-being is a significant concern. Therefore, we developed an interdisciplinary psychoeducational intervention program for children named CARTOON. …”

Supplementary Material for: Long-term outcomes and clinical factors associated with conventional therapy failure in intestinal Behçet’s disease: A retrospective cohort study in Jap... by figshare admin karger (2628495)

“…Concomitant glucocorticoid use significantly decreased from 12.7±11.7 mg/day at baseline to 2.4±2.5 mg/day at 1 year (p<0.001). …”

Table 1_Associations of specific food sources of dietary fat with prostate cancer incidence and mortality: results from a large prospective cohort.docx by Yong-xin Fu (22644743)

“…However, a greater intake of plant-based monounsaturated fatty acids (MUFAs; HR _Q4vs.Q1: 0.67; 95% CI: 0.48–0.94; P_trend = 0.023), plant-based SFAs (HR _Q4vs.Q1:0.65; 95% CI: 0.47–0.91; P_trend = 0.026) and polyunsaturated fatty acids (PUFAs) from fish (HR _Q4vs.Q1: 0.48; 95% CI: 0.48–0.87; P_trend = 0.005) was associated with a decreased PCa mortality in a non-linear dose-response relationships (all P_{non − linearity} < 0.05). …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”